Definium Therapeutics Inc (DFTX) Says Cash Enough to Fund Operations into 2028

Definium Therapeutics Inc (NASDAQ:DFTX) is among the best psychedelic stocks to buy in 2026. The company’s flagship drug candidate, DT120, is undergoing Phase 3 trials for the treatment of major depressive disorder (MDD), generalized anxiety disorder (GAD), and other psychiatric conditions. Its other drug candidate, DT402, targets autism spectrum disorder and is undergoing Phase 2 trials.

Definium Therapeutics Inc (NASDAQ:DFTX) plans to host its Investor and Analyst Day on April 22. It plans to use the event to discuss DT120 program updates as well as commercial opportunities.

On February 26, Definium Therapeutics released its 2025 financial results and provided updates about its business. On the financial side, the company said it spent $117.7 million on R&D in 2025. General and administrative-related spending consumed $48.6 million. That said, the company exited 2025 with $411.6 million in cash and cash equivalents and investments. According to the management, this cash amount and expected milestones should be enough to bankroll the company’s operations into 2028.

Regarding business updates, Definium Therapeutics said it had completed enrollment for the Emerge Phase 3 MDD trial for DT120. Topline data from that study is expected in late Q2 2026. It further said enrollments for the two Phase 3 GAD trials for DT120 are progressing well. For the Phase 2a trial for DT402 that kicked off in Q4 2025, initial study data are expected in 2026.

Definium Therapeutics Inc (NASDAQ:DFTX) is an American clinical biopharmaceutical company headquartered in New York. The company is focused on developing drugs to treat mental health disorders. Its lead drug candidate DT120, currently in Phase 3 trial, targets major depressive disorder (MDD), generalized anxiety disorder (GAD), and other brain health conditions.

While we acknowledge the risk and potential of DFTX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than DFTX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.